HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?

The article evaluates cancer diagnostics firms Hologic (HOLX) and Exact Sciences (EXAS), concluding EXAS presents a more compelling investment case. Exact Sciences benefits from strong Cologuard momentum, a robust innovation pipeline including recent product launches and upcoming multi-cancer early detection tests, and significant operational efficiency, reflected in a 61% YoY adjusted EBITDA increase and a projected 169.6% EPS improvement for fiscal 2025. In contrast, Hologic, despite a diversified portfolio and strong balance sheet, faces headwinds such as $20M-$25M quarterly tariff costs, softer capital equipment demand, and downward-trending EPS estimates, leading to a 15.9% share decline over the past year compared to EXAS's 7.4% gain.

Analysis

The comparative analysis of Hologic (HOLX) and Exact Sciences (EXAS) highlights a significant divergence in their current operational trajectories and market outlooks within the growing cancer diagnostics sector. Exact Sciences is demonstrating strong momentum, driven by its flagship Cologuard test and a robust innovation pipeline. The company's recent launches of Cologuard Plus and the Oncodetect MRD test, both with secured Medicare coverage, reinforce its growth narrative. Operationally, EXAS has shown substantial improvement, with a 61% year-over-year increase in adjusted EBITDA and a projected 169.6% surge in fiscal 2025 EPS. This positive outlook is reflected in its 7.4% share price gain over the past year and its insulation from tariffs due to U.S.-based operations. In contrast, Hologic faces considerable headwinds despite its diversified portfolio and strong balance sheet. The company is grappling with an anticipated $20 million to $25 million quarterly inventory cost increase from tariffs, softer capital equipment demand, and the loss of its HIV testing business in Africa. These challenges are mirrored in its stock's 15.9% decline over the past year and downward-trending EPS estimates, which project a modest 2.7% growth. While HOLX maintains a dominant market share in mammography and a solid 30% operating margin, the combination of external pressures and market-specific softness presents a more challenging near-term picture compared to the clear growth catalysts propelling Exact Sciences.

Key Decisions for Investors

• Given its strong product momentum, successful new test launches with Medicare reimbursement, and bullish analyst sentiment, investors may find Exact Sciences (EXAS) to be a compelling growth opportunity, but should monitor its high debt levels.
• For Hologic (HOLX), investors should exercise caution and closely monitor the financial impact of tariffs, a potential recovery in capital equipment sales, and any further revisions to its EPS estimates, as these are significant headwinds.
• The valuation disparity, with EXAS trading at a lower forward P/S multiple (2.76x) than HOLX (3.47x) despite a stronger growth outlook and positive stock performance, suggests a potential relative value opportunity favoring EXAS.
• Consider the divergent narratives for a potential pairs trade, going long EXAS to capture its pipeline and operational momentum while shorting or remaining underweight HOLX to hedge against its specific macroeconomic and operational risks.